Human cord blood as a source of neural tissue for repair of the brain and spinal cord

• US 7,160,724 B2
• Filed: 03/07/2001
• Issued: 01/09/2007
• Est. Priority Date: 03/09/2000
• Status: Expired due to Term

• Current Assignee: Saneron CCEL Therapeutics, Inc., University of South Florida (State University System of Florida)
• Original Assignee: University of South Florida (State University System of Florida)
• Inventors: Sanberg, Paul, Sanchez-Ramos, Juan, Willing, Alison, Richard, Daniel D.
• Primary Examiner(s): FALK, ANNE MARIE
• Application Number:
  US09/801,221
• Publication Number:
  US 20020028510A1
• Time in Patent Office: 2,134 Days
• Field of Search: 435/325, 435/352, 435/354, 435/360, 435/366, 435/368, 435/377, 435/383, 435/384, 435/385, 435/386, 435/387, 435/375, 435/455, 435/372, 424/93.1, 424/93.7
• US Class Current: 435/377
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/32 Alcohol-abuse
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2501/13 Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
• CPC Class Codes: C12N 2501/385 of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
• CPC Class Codes: C12N 2506/1369 from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
• CPC Class Codes: C12N 5/0618 Cells of the nervous system

Abstract

The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.

Claims

1. A method of producing an isolated, differentiated, mononuclear cell from human umbilical cord blood, comprising:

a) obtaining a cord blood fraction comprising mononuclear cells from said umbilical cord blood, wherein the mononuclear cells comprise progenitor cells;

b) growing the mononuclear cells in a serum-free medium comprising EGF and bFGF to produce an enriched fraction of progenitor cells; and

c) culturing the enriched fraction of progenitor cells in a culture medium containing an effective amount of retinoic acid and nerve growth factor (NGF) for a period sufficient to differentiate the progenitor cells to cells bearing neural progenitor markers.

2. The method of claim 1, wherein the retinoic acid is selected from the group consisting of 9-cis retinoic acid, all transretinoic acid and a mixture thereof.